CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 263 enrolled
Drug / intervention
insulin degludec/insulin aspart +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02648217
NCT02648217Phase 3Completed
CompareCT.gov

A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Novo Nordisk A/S·interventional·Posted Jan 6, 2016·Updated Sep 11, 2018

In Brief

A Phase 3 clinical trial evaluating insulin degludec/insulin aspart and biphasic insulin aspart for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 263 participants across 32 sites in 6 countries.

Detailed Summary

This trial is conducted in Africa and Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart twice daily and biphasic insulin aspart twice daily in subjects with type 2 diabetes mellitus before, during and after Ramadan.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesAlgeria, India, Lebanon, Malaysia, South Africa, United Arab Emirates
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 6, 2016
Enrollment StartJan 4, 2016
Primary CompletionSep 4, 2016
Study CompletionSep 5, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 10.5 years ago

Interventions

insulin degludec/insulin aspartdrug

Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.

biphasic insulin aspartdrug

Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.